Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. ZVSA was recently a guest on Benzinga’s All-Access.
ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.
The technologies could represent a leap forward in the treatment of several diseases.
Watch the full interview here:
Featured photo by Hans Reniers on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
